Intangible Assets, Net (Details) - USD ($) |
6 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
May 31, 2025 |
Dec. 31, 2024 |
May 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Intangible Assets, Net [Line Items] | |||||||
| Impairment loss amount | $ 128,128 | $ 519,496 | |||||
| Loss on disposal of patented license | $ 205,189 | ||||||
| Amortization expenses for finite-lived intangible assets | $ 19,219 | $ 19,219 | 84,020 | $ 114,553 | |||
| Intangible assets | 147,347 | ||||||
| DiamiR Biosciences Corp. [Member] | |||||||
| Intangible Assets, Net [Line Items] | |||||||
| Impairment loss amount | |||||||
| Research and development expenses | 2,236 | ||||||
| Intangible assets | $ 197,761 | $ 197,761 | |||||
| Hong Kong healthcare services [Member] | |||||||
| Intangible Assets, Net [Line Items] | |||||||
| Research and development expenses | $ 128,128 | $ 1,841 | |||||
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of intangible assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|